
About Laevoroc Oncology
Laevoroc Oncology is a Healthcare company based in Hunenberg (Switzerland) founded in 2019 by Davide Guggi. Therapeutics for pancreatic, ovarian, breast, and brain cancers are developed. Laevoroc Oncology has raised $1.1 million across 1 funding round. Laevoroc Oncology offers products and services including LR09, LR06, and LR02. Its focus areas include Life Sciences, Neurology, Drugs and Brain Cancer. Its legal entity is Laevoroc Oncology AG.
Company details
Developer of therapeutics for cancer. The drug candidates include LR 06 an oral gemcitabine prodrug for pancreatic, ovarian, and breast cancers, LR09 guides the immune system to eradicate relapsed leukemia after allogeneic stem cell transplantation, and LR02 is a central nervous system ATR inhibitor for treating brain cancer.
- Headquarters Hunenberg, Switzerland
- Founders Davide Guggi
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website laevoroc.com
- Social LinkedIn YouTube
- Legal Name Laevoroc Oncology Ag
- Total Equity Funding$1.1M (USD)
in 1 rounds
- Latest Funding Round$1.1M (USD), Seed
May 2021
Products & Services of Laevoroc Oncology
Laevoroc Oncology offers a comprehensive portfolio of products and services, including LR09, LR06, and LR02.
Inhibitor targeting relapsed leukemia after stem cell transplantation
Oral prodrug for maintenance therapy in various cancers
Inhibitor for brain cancer treatment with CNS penetration
Apps and channels of Laevoroc Oncology
its YouTube channel LAEVOROC Oncology has 0026 subscribers.
Funding Insights of Laevoroc Oncology
Laevoroc Oncology has successfully raised a total of $1.1M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.1 million completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.1M
- Total Rounds 1
- Last Round Seed β $1.1M
- First Round $1.1M
(May 2021)
All 1 funding rounds of Laevoroc Oncology with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2021 | $1.1M | Seed | β | β | β |
People of Laevoroc Oncology
4 people are tracked at Laevoroc Oncology (4 in leadership).
| Name | Role | Group |
|---|---|---|
Davide Guggi | Co-Founder | Leadership |
Thomas Mehrling | Founder-ceo At Laevoroc | Leadership |
Jessica Kourniakti, DPhil | Chief Operating Officer | Leadership |
Shanta Bantia | Co-founder - CSO At Laevoroc Immunology | Leadership |
Complete people profiles for Laevoroc Oncology
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Laevoroc Oncology
2 dated milestones of Laevoroc Oncology across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Laevoroc Oncology is founded.
- Funding First funding round of $1.1M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Laevoroc Oncology
Complete news archive for Laevoroc Oncology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Laevoroc Oncology
Laevoroc Oncology was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Laevoroc Oncology is headquartered in Hunenberg, Switzerland. It is registered at Hunenberg, Zug, Switzerland.
Laevoroc Oncology is a funded company, having raised a total of $1.1M across 1 funding round to date. The company's 1st funding round was a Seed of $1.1M, raised on May 2021.
Developer of therapeutics for cancer. The drug candidates include LR 06 an oral gemcitabine prodrug for pancreatic, ovarian, and breast cancers, LR09 guides the immune system to eradicate relapsed leukemia after allogeneic stem cell transplantation, and LR02 is a central nervous system ATR inhibitor for treating brain cancer.
Laevoroc Oncology offers LR09, LR06, and LR02.
Laevoroc Oncology operates through Laevoroc Oncology Ag.
